The Flin Flon/Snow Lake/Cranberry Portage/Sherridon district is sitting at eight active cases of COVID-19 as of May 11, reporting two new cases Tuesday. Other districts that reported new cases include the Bunibonibee/Oxford House/Manto Sipi/Gods River/Gods Lake, Cross Lake/Pimicikamak, Island Lake and The Pas/OCN/Kelsey districts. A total of 13 people from the north are hospitalized due to COVID-19 as of May 11, including one person now in intensive care. There are now 275 active cases of COVID-19 in the NHR. No new outbreaks or possible community exposures to COVID-19 were announced in the NHR May 11.
WINNIPEG A new class-action lawsuit has been filed focusing on Revera-owned Maples Personal Care Home in Winnipeg. According to a news release from Diamond and Diamond Lawyers, the lawsuit was filed on May 10, and names AXR Operating Inc. and the Winnipeg Regional Health Authority as defendants as well. The lawsuit is in response to a COVID-19 outbreak at the facility in October, which resulted in the deaths of 56 people. During this outbreak, 157 residents contracted the disease, as well as 74 staff members. Diamond and Diamond notes that an independent review of the facility found that it was not prepared for the reduction in staff brought on by the outbreak and that the new workers brought in were not properly trained in prevention and control.
Posted: May 12, 2021 5:00 AM CT | Last Updated: May 12
Eddie Calisto-Tavares took a photo of herself and her father, Manuel Calisto, in the Maples Long Term Care Home during the outbreak. Manuel Calisto died on Nov. 11.(Submitted by Eddie Calisto-Tavares )
The families of two residents who died of COVID-19 complications during the Maples Long Term Care Home outbreak last fall have launched a class-action lawsuit against Revera, the for-profit company that owns the facility, and the Winnipeg Regional Health Authority, which funds and oversees it.
The lawsuit alleges Revera and the health authority caused or contributed to the COVID-19 deaths of Ethel Lewsey, 99, and Manuel Calisto, 88.
Utility Therapeutics Ltd.: UTILITY Therapeutics Announces Scientific Advisory Board
SAB includes key opinion leaders for infectious diseases and urinary tract infections
LONDON, UK / ACCESSWIRE / May 11, 2021 / UTILITY therapeutics Ltd., a biotechnology company focused on the U.S. development and commercialization of two European-approved antibiotics for the treatment of urinary tract infections (UTI), announced today that it has established a Scientific Advisory Board (SAB) that will be chaired by Keith A. Rodvold, PharmD and Distinguished Professor
of Pharmacy at the College of Medicine at the University of Illinois in Chicago. We are honored to have such a prestigious and experienced group of medical and industry experts join our Scientific Advisory Board, stated Tom Hadley, President and Chief Commercial Officer of UTILITY therapeutics. Their guidance will be extremely valuable as we advance our two product candidates for the treatment of UTIs. We look forward to working